Table 1.
The demographic and clinical characteristics of HSHZ, Chaoyang and Youan HCC‐LT cohorts.
| Variables | HSHZ (n = 342) | Chaoyang (n = 119) | Youan (n = 205) | P value |
|---|---|---|---|---|
| Blood type | ||||
| A | 78 (26%) | 27 (22.7%) | 57 (27.8%) | 1.97E‐01 |
| AB | 27 (9%) | 17 (14.3%) | 32 (15.6%) | |
| B | 93 (31%) | 40 (33.6%) | 63 (30.7%) | |
| O | 102 (34%) | 35 (29.4%) | 53 (25.9%) | |
| Gender | ||||
| Female | 30 (8.8%) | 12 (10.1%) | 22 (10.7%) | 7.39E‐01 |
| Male | 312 (91.2%) | 107 (89.9%) | 183 (89.3%) | |
| Age | ||||
| ≤60 | 269 (82.8%) | 80 (67.2%) | 156 (76.1%) | 1.75E‐03 |
| >60 | 56 (17.2%) | 39 (32.8%) | 49 (23.9%) | |
| AFP | ||||
| ≤200 | 201 (67.2%) | 88 (73.9%) | 138 (67.3%) | 3.68E‐01 |
| >200 | 98 (32.8%) | 31 (26.1%) | 67 (32.7%) | |
| PT | ||||
| ≤13 | 138 (41.7%) | 33 (27.7%) | 80 (39%) | 2.63E‐02 |
| >13 | 193 (58.3%) | 86 (72.3%) | 125 (61%) | |
| HBsAg | ||||
| Negative | 62 (20.5%) | 43 (36.1%) | 45 (22%) | 2.38E‐03 |
| Positive | 240 (79.5%) | 76 (63.9%) | 160 (78%) | |
| HCV | ||||
| Negative | 294 (97.4%) | 115 (96.6%) | 192 (93.7%) | 1.06E‐01 |
| Positive | 8 (2.6%) | 4 (3.4%) | 13 (6.3%) | |
| Tbil | ||||
| ≤23 | 159 (49.8%) | 47 (39.5%) | 87 (42.4%) | 8.51E‐02 |
| >23 | 160 (50.2%) | 72 (60.5%) | 118 (57.6%) | |
| Alb | ||||
| ≤35 | 93 (29.2%) | 62 (52.1%) | 86 (42%) | 1.64E‐05 |
| >35 | 226 (70.8%) | 57 (47.9%) | 119 (58%) | |
| PLT | ||||
| ≤100 | 157 (49.5%) | 74 (62.2%) | 36 (17.6%) | 1.35E‐17 |
| >100 | 160 (50.5%) | 45 (37.8%) | 169 (82.4%) | |
| AJCC | ||||
| T1‐T2 | 233 (68.1%) | 104 (87.4%) | 163 (79.5%) | 3.32E‐05 |
| T3‐T4 | 109 (31.9%) | 15 (12.6%) | 42 (20.5%) | |
| Milan criteria | ||||
| No | 236 (69%) | 56 (47.1%) | 115 (56.1%) | 2.72E‐05 |
| Yes | 106 (31%) | 63 (52.9%) | 90 (43.9%) | |
| UCSF criteria | ||||
| No | 187 (54.7%) | 27 (22.7%) | 99 (48.3%) | 1.21E‐08 |
| Yes | 155 (45.3%) | 92 (77.3%) | 106 (51.7%) | |
| Tumor Number | ||||
| >1 | 168 (49.1%) | 44 (37%) | 123 (60%) | 2.81E‐04 |
| 1 | 174 (50.9%) | 75 (63%) | 82 (40%) | |
| Max tumor diameter (cm) | ||||
| ≤5 | 216 (63.2%) | 91 (76.5%) | 143 (69.8%) | 2.04E‐02 |
| >5 | 126 (36.8%) | 28 (23.5%) | 62 (30.2%) | |
| MVI | ||||
| No | 89 (26%) | 50 (42%) | 145 (70.7%) | 1.78E‐23 |
| Yes | 253 (74%) | 69 (58%) | 60 (29.3%) | |
| PVTT | ||||
| No | 257 (75.1%) | 107 (89.9%) | 183 (89.3%) | 8.29E‐06 |
| Yes | 85 (24.9%) | 12 (10.1%) | 22 (10.7%) | |
| Differentiation | ||||
| G1‐G2 | 177 (63.9%) | 92 (78.6%) | 105 (61%) | 4.62E‐03 |
| G3‐G4 | 100 (36.1%) | 25 (21.4%) | 67 (39%) | |
| Intra‐tumoral TLS | ||||
| High | 170 (49.7%) | 60 (50.4%) | 79 (38.5%) | 2.50E‐02 |
| Low | 172 (50.3%) | 59 (49.6%) | 126 (61.5%) | |
| Peri‐tumoral TLS | ||||
| High | 220 (64.3%) | 106 (89.1%) | 150 (73.2%) | 1.41E‐06 |
| Low | 122 (35.7%) | 13 (10.9%) | 55 (26.8%) | |
AFP, α‐fetoprotein; PT, Prothrombin time; PLT, Platelet; AJCC, American Joint Committee on Cancer; UCSF, University of California San Francisco; MVI, microvascular invasion; PVTT, Portal vein tumor thrombus.